Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QAE 397

Drug Profile

QAE 397

Alternative Names: QAE397

Latest Information Update: 12 Jul 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antirheumatics; Corticosteroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 29 Jun 2011 Discontinued - Phase-II for Asthma in Italy (Inhalation)
  • 28 Jul 2010 No development reported - Phase-II for Asthma in Italy (Inhalation)
  • 19 Jan 2006 Discontinued - Phase-I for Chronic obstructive pulmonary disease (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top